牛脾转移因子及白三烯C4与异位性皮炎

用牛脾转移因子口服液（ＯＢＳ－ＴＦ）治疗异位性皮炎（ＡＤ）２ 例，井采用3Ｈ放兔法测定了ＯＢＳ－ＴＦ治疗前后ＡＤ患者及正常人血浆及外周血白细胞（ＰＢＬ）中白三烯Ｃ４（ＬＴＣ４）含量。ＡＤ血浆及ＰＢＬ中ＬＴＣ４含量治疗前均明显高于正常人，治疗后则无显著差异，ＡＤ的严重程度与ＬＴＣ４水平相乎行，提示ＬＴＣ４可能作为强效炎症介质之一介入了ＡＤ的发病过程， ＯＢＳ－ＴＦ则可能作为ＬＴＣ４的抑制剂对ＡＤ发挥了治疗作用。     

基于网络药理学探讨肛肠瘙痒洗剂治疗肛周湿疹的作用机制

目的:基于网络药理学方法初步探讨肛肠瘙痒洗剂治疗肛周湿疹的机制.方法:应用TCMSP数据库,根据DL≥0.18,ALogP<0.5对成分信息进行筛选后,检索药物相关靶点,共获得药物靶点258个.在GeneCards数据库中查找"湿疹"疾病相关基因,共获得相关基因2736个.药物和疾病共有靶点114个.使用String数...     

地奈德乳膏联合三重滋润霜治疗婴幼儿面部干燥性湿疹疗效观察

目的：了解0.05%地奈德乳膏联合三重滋润霜治疗秋冬季节婴幼儿面部干燥性湿疹的疗效及安全性。方法：采用随机对照开放试验,治疗组给予地奈德乳膏和三重滋润霜外用,均为2次/天,错时使用,待皮疹痊愈后改用三重滋润霜2次/天维持;对照组仅给予0.05%地奈德乳膏外用,2次/天,待皮疹痊愈后地奈德乳膏改为1次/天,连用3天。于就诊的当日,用药的第3、5、7、10天,皮疹痊愈后7天复诊,记录皮疹变化,对红斑、丘疹、鳞屑及瘙痒的总积分进行评价。结果：治疗组在治疗的第3、5、7天的显效率均高于对照组;治疗组在治疗的第10天显效率与对照组相当,在痊愈后7天复查时的痊愈率高于对照组。结论：三重滋润霜针对婴幼儿面部干燥性湿疹的皮损和瘙痒具有较好的辅助治疗作用,在临床有一定的推广价值。     

育阴化湿汤治疗慢性期特应性皮炎疗效及对IL-4与INF-γ的影响

目的 :探讨慢性期特应性皮炎应用育阴化湿汤的临床疗效及对免疫状态的影响。方法 :随机选取我院2013年6月~2015年12月收治的慢性期特应性皮炎患儿74例作为研究对象,随机分为两组,对照组常规服用抗组胺药左西替利嗪片,观察组在对照组治疗基础上加服育阴化湿汤治疗,疗程4周。对比分析两组患儿临床疗效、治疗前后血清白介素-4(IL-4)以及干扰素γ(INF-γ)水平。结果:观察组患儿治疗总有效率明显高于对照组(P0.05),治疗后观察组血清IL-4水平较对照组明显下降(P0.05),观察组INF-γ水平较对照组明显升高(P0.05)。结论:育阴化湿汤治疗慢性期特应性皮炎患儿临床疗效显著,且能降低血清IL-4水平并使INF-γ水平升高,调节Th1/Th2平衡,改善患儿免疫失衡状态。     

朱仁康治疗湿疹用药规律分析

目的:分析朱仁康治疗湿疹的用药规律,明晰其经验与学术思想。方法:以朱仁康教授门诊病历为数据源,运用中国中医科学院中药信息研究所研发的“古今医案云平台V1.4”软件,采用频数分析、关联规则分析方法进行数据挖掘,确定处方中核心药物组合、用药模式及药物间的关联规则等。结果:本研究共收集湿疹患者168例、190诊次、临床表现190个、舌质65个、舌苔75个、脉象60个、方剂130个、中药130味,挖掘出湿疹常见临床症状、常用中药以及药物四气、五味、归经的频数分布;四诊信息、中药的聚类现象;中药与中药、症状与中药的关联规则;核心药物组合的复杂网络。结论:常用药有30味;用药以寒凉为主,兼以温药;苦泻淡渗为主,兼用辛甘;调理心、脾为主,兼治肺、肝、肾、膀胱;常用组合有8组及随症加减常用药。     

基于医学社交媒体数据的多模态知识图谱构建

介绍医学领域传统知识图谱研究现状,分析医学社交媒体数据发展情况,详细阐述基于医学社交媒体数据的多模态知识图谱构建方法,提出多模态知识图谱构建成为必然趋势,多模态知识融合有助于进一步提高医学专家系统的智能性。     

Probiotic supplementation in the first 6 months of life in at risk Asian infants – effects on eczema and atopic sensitization at the age of 1 year

Background The role of probiotics in allergy prevention remains uncertain but has been shown in some studies to have a possible protective effect on eczema. Objective We aimed to assess the effect of probiotic supplementation in the first 6 months of life on eczema and allergic sensitization at 1 year of age in Asian infants at risk of allergic disease. Methods A double‐blind, placebo‐controlled randomized clinical trial involving 253 infants with a family history of allergic disease was carried out. Infants received at least 60 mL of commercially available cow's milk formula with or without probiotic supplementation [Bifidobacterium longum (BL999) 1 × 10⁷ colony forming unit (CFU)/g and Lactobacillus rhamnosus (LPR) 2 × 10⁷ CFU/g] daily for the first 6 months. Clinical evaluation was performed at 1, 3, 6 and 12 months of age, with serum total IgE measurement and skin prick tests conducted at the 12‐month visit. The primary and secondary end‐points were eczema and allergen sensitization, respectively. Results The incidence of eczema in the probiotic (22%) group was similar to that in the placebo group (25%) (P=0.53). The median Scoring Atopic Dermatitis score at 12 months was 17.10 (9.74) in the probiotic group and 11.60 (8.40) in the placebo group (P=0.17). The prevalence of allergen sensitization showed no difference (probiotic=24% vs. placebo=19%, P=0.26). The total IgE geometric mean (95% confidence interval) was 18.76 (12.54–24.98) kU/L in the probiotic group and 23.13 (16.01–30.24) kU/L in the placebo group (P=0.15). Atopic eczema (with sensitization) in the probiotic (7.3%) group was comparable to the placebo group (5.8%) (P=0.86). Conclusion Early life administration of a cow's milk formula supplemented with probiotics showed no effect on prevention of eczema or allergen sensitization in the first year of life in Asian infants at risk of allergic disease. Further work is needed to determine whether timing of supplementation, dose and probiotic strain are important considerations.